Allogene Therapeutics ALLO Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$42.61M-9.8% | -$38.81M+6.3% | -$41.4M+18.7% | -$50.94M+14.7% | -$59.73M+0.3% | ||
| $2.87M-6.1% | $3.06M-1.3% | $3.1M-0.3% | $3.11M+0.2% | $3.1M-4.1% | ||
| $8.27M+1.7% | $8.13M-6.0% | $8.65M-0.4% | $8.69M-28.7% | $12.18M-5.4% | ||
| $663K— | —— | -$1.07M-154% | -$422K-25.6% | -$336K— | ||
| -$5.1M-4,223% | -$118K— | —— | —— | -$5.22M— | ||
| -$84K-182% | $102K— | —— | $1.93M+554% | -$425K+38.2% | ||
| $316K-4.0% | $329K-8.4% | $359K+26.9% | $283K+72.6% | $164K+72.6% | ||
| -$2.2M-16.6% | -$1.89M-1.8% | -$1.86M+3.7% | -$1.93M-5.1% | -$1.83M-3.2% | ||
| -$12.91M+53.2% | -$27.6M+7.0% | -$29.69M+23.9% | -$39.03M+26.3% | -$52.93M-44.2% | ||
| $9K— | $0-100% | $243K+452% | $44K-55.6% | $99K-61.5% | ||
| $101.69M+258% | $28.38M-42.9% | $49.73M+401% | $9.92M-80.2% | $50.23M+6.9% | ||
| $72.12M— | $0+100% | -$110.3M-305% | $53.8M-4.8% | $56.5M— | ||
| -$29.59M-188% | $33.61M+182% | $11.94M-72.8% | $43.84M+610% | $6.18M-88.8% | ||
| $450K— | —— | $257K— | —— | $10M— | ||
| $21.12M+169% | $7.86M+143% | $3.24M-36.2% | $5.07M-63.7% | $13.99M+144% | ||
| -$21.38M— | —— | -$14.52M— | —— | -$32.76M— | ||
| -$5.1M-4,223% | -$118K— | —— | —— | -$5.22M— | ||
| -$23.48M-335,514% | $7K— | $0-100% | $1.84M+112% | $868K— | ||
| -$2.2M-16.6% | -$1.89M-1.8% | -$1.86M+3.7% | -$1.93M-5.1% | -$1.83M-3.2% | ||
| $316K-4.0% | $329K-8.4% | $359K+26.9% | $283K+72.6% | $164K+72.6% | ||
| -$1.13M-14.8% | -$986K+2.4% | -$1.01M+45.8% | -$1.87M-399% | $623K— | ||
| $885K+7.8% | $821K-11.1% | $923K-21.2% | $1.17M-10.3% | $1.31M-20.9% | ||
| $3.23M-0.1% | $3.24M+2.2% | $3.17M-3.8% | $3.29M+2.0% | $3.23M+0.9% | ||
| $72.12M+16.3% | $61.99M+0.1% | $61.91M+15.1% | $53.8M-4.8% | $56.5M-44.7% | ||
| $0— | —— | —— | $3.56M+6.2% | $3.35M— | ||
| $4K— | $0— | $0— | $0— | $0— | ||
| $450K— | —— | $257K— | —— | $638K— | ||
| $146K— | —— | —— | $215K— | $0-100% | ||
| -$2.2M-16.6% | -$1.89M-1.8% | -$1.86M+3.7% | -$1.93M-5.1% | -$1.83M-3.2% | ||
| $1.07M+2.1% | $1.05M+1.6% | $1.03M-10.1% | $1.15M+1.5% | $1.13M+1.3% | ||
| -$12.92M+53.2% | -$27.6M+7.8% | -$29.93M+23.4% | -$39.07M+26.3% | -$53.03M-43.5% | ||
| -$12.92M+53.2% | -$27.6M+7.8% | -$29.93M+23.4% | -$39.07M+26.3% | -$53.03M-43.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Allogene Therapeutics generate?
- Allogene Therapeutics (ALLO) generated -$109.2M in operating cash flow over the trailing twelve months.
- What is Allogene Therapeutics's free cash flow?
- After $296.0K of capital expenditures, Allogene Therapeutics's free cash flow was -$109.5M over the trailing twelve months, up 44.7% year over year.
- Where does Allogene Therapeutics's cash flow data come from?
- Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.